Navigation Links
New Findings from Miraca Life Sciences Research Institute Slated for Release at ACG 2013
Date:9/25/2013

Irving, Texas (PRWEB) September 25, 2013

Findings from seven research studies conducted by the Miraca Life Sciences Research Institute have been selected for presentation at this year’s American College of Gastroenterology annual scientific meeting. Beginning Sunday, October 13, 2013 through Tuesday, October 15, attendees at the San Diego-based meeting will have an opportunity to review these seven studies, and learn about the specific clinical utility of these investigations to benefit patient care.

Dr. Robert M. Genta, Chief of Academic Affairs at the Miraca Life Sciences Research Institute and a Clinical Professor of Pathology and Gastroenterology at the University of Texas Southwestern Medical Center at Dallas, noted that the studies are based upon data from the company’s extensive repository of histopathologic, demographic and clinical patient information and represent important advancements in patient care.

Dr. Genta said, “With more than 5 million patients in our database, each complete with demographic, endoscopic, and clinical data, we are in a unique position to carry out nation-wide clinicopathologic research projects. The studies reported at this year’s meeting, as well as some studies recently published by Miraca Life Sciences pathologists, are prime examples of the broad cross-section of demographics and disease states that can lie at the foundation of our research endeavors.”

The seven studies by pathologists at Miraca Life Sciences include new insights suggesting that Eosinophilic Esophagitis and inflammatory bowel disease (IBD) may share a common immunopathogenetic mechanism; how the role of HIV infection and CD4 cells affect gastric mucosal response; and strong data supporting the assertion that Helicobacter-negative Chronic Active Gastritis occurs as a distinct condition, unrelated to H. pylori infection.

Another study confirmed the inverse relationship between Eosinophilic Esophagitis (EoE) and H. pylori infection (previously reported by Lash and Genta from Miraca Life Sciences in collaboration with researcher from the University of North Carolina) and expanded the observations to other conditions of the stomach, including autoimmune atrophic gastritis.

The Miraca Research Institute efforts, Dr. Genta says, “address diverse gastroenterological conditions that have widespread prevalence and incur significant burden to an individual’s quality of life, and expense to our health system.”

“It is imperative to develop new approaches in diagnosis and therapy. These can best develop from research that examines large amounts of data for nuances of pathologic relationships that would be undiscoverable in small studies, giving us insights to advance quality care and treatment outcomes in these populations.”

Also to be presented are conclusions from the largest clinicopathologic series of patients with documented spirochetosis, which found that the condition may be asymptomatic in more than half of the subjects infected. Researchers will also discuss the unexpected finding of fungal esophagitis in patients with endoscopically unremarkable esophagus, and how patients with diarrhea and microscopic colitis (MC) have a significantly lower prevalence of colorectal polyps, suggesting inhibition of epithelial proliferation by regulatory T-cells.

About Miraca Life Sciences

Serving more than 3,500 patients each day, Miraca Life Sciences is a leader in providing an academic-caliber pathology laboratory with diagnostic services in the fields of dermatology, gastroenterology, hematology and urology. Building upon our experience with health IT, we also offer accessible technology solutions to assist healthcare professionals as they work towards accordance with Meaningful Use initiatives.

Miraca Life Sciences, a wholly-owned subsidiary of Japan-based Miraca Holdings Inc., employs a talented team of leading pathologists, histologists, lab technicians, technology consultants, and other medical professionals — all driven to help provide the highest and most up-to-date levels of diagnostic quality, enhanced workflow and practice solutions possible. It is part of our commitment: not only to scientific excellence, but to patients and practices.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11152747.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Reassuring findings for mothers who have influenza vaccine while pregnant
2. Figurella Announces Findings That Show Their Method Can Fight Cellulite from Inside
3. ChanTest Announces a Global Campaign to Share New Findings and Developments in Cystic Fibrosis Research
4. Da Vinci Robot Lawsuit News: Bernstein Liebhard LLP Comments on New Study Findings that Casts Doubt on Robot-Assisted Hysterectomy
5. Pradaxa Lawsuit News: Bernstein Liebhard LLP Comments on Study Findings Regarding Use of Pradaxa in Mechanical Heart Valve Patients
6. Newest Bard IVC Filter Failure Lawsuit Allegations Update: Resource4thePeople Urges Consumers to Review FDA, Research Study Findings about Adverse Events
7. Liquid Grids Releases Findings from Three Case Studies, Validating Direct to Persona Marketing for Healthcare
8. New findings could influence the development of therapies to treat dengue disease
9. Rancid Fish Oil Capsules May Partly Explain Omega-3 and Prostate Cancer Findings, Suggest Co-founders of Omega3 Innovations
10. New study describes imaging findings in H7N9 influenza
11. New Survey Findings: Application Intelligence and Connected Devices - How do you Harness the Value?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... the perils of heroin that was watched live by 1 million viewers and ... duPont-Columbia University Award. , ASU students at the Walter Cronkite School of Journalism ...
(Date:12/2/2016)... ... December 02, 2016 , ... More ... in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, ... funds for area students and operating support to UNCF-member institutions, including Miles College, ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... , ... December 02, 2016 , ... More than half ... while 84 percent of parents report speaking with their child about sex related topics, ... transmitted diseases. , Mediaplanet is proud to announce the launch of its second edition ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... According to a new ... Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, ... Infectious Diseases) - Forecast to 2021" published by ... 60.22 Billion in 2016. This market is expected ... the forecast period (2016-2021) to reach USD 78.74 ...
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... -- Boston Scientific Corporation (NYSE: BSX ) ... assets and capabilities of the Neovasc, Inc., (NASDAQ: ... as well as a 15% equity stake in Neovasc, ... Neovasc advanced biological tissue business makes elements used in ... System. * Upon completion of the transaction, the ...
Breaking Medicine Technology: